Psoriasis Redefined
Webinar Series
The next innovation in skin has arrived.
A series of three CPD certified modules, presented by recognised experts in clinical psoriasis to support you should you decide to use BIMZELX® ▼ (bimekizumab) for treating your eligible adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Help us to grow our resource the way you want it to grow.